Effects of Two Different Kinesiotaping Techniques in Carpal Tunnel Syndrome (NCT07742293) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effects of Two Different Kinesiotaping Techniques in Carpal Tunnel Syndrome
90 participantsStarted 2026-08
Plain-language summary
This study aims to evaluate the clinical, functional, and ultrasonographic effects of two different kinesiotaping techniques added to a standard exercise and night splint program in the treatment of Carpal Tunnel Syndrome (CTS). Participants will be randomly assigned to one of three groups: the I-Strip kinesiotaping technique group, the Button Hole kinesiotaping technique group, or a control group receiving only standard therapy. The study will assess treatment outcomes over a 12-week period using high-resolution ultrasound (specifically median nerve cross-sectional area and flattening ratio) and clinical parameters to determine the most effective conservative management approach.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Being aged between 18 and 65 years.
* Willingness and ability to sign the informed consent form.
* Having symptoms of carpal tunnel syndrome (hand numbness, tingling, pain) for at least 3 months.
* Clinical diagnosis of mild-to-moderate carpal tunnel syndrome confirmed by physical examination (positive Phalen/Tinel tests) and a prior nerve conduction study (EMG).
Exclusion Criteria:
* Previous wrist or hand surgery.
* Severe carpal tunnel syndrome on EMG (evidence of thenar atrophy or severe motor loss).
* History of trauma, fracture in the wrist area, or anatomical anomalies affecting ultrasonography.
* Cervical radiculopathy, polyneuropathy, diabetic neuropathy, or other concomitant upper extremity entrapment neuropathies.
* Local corticosteroid injection to the carpal tunnel within the last 6 months.
* Pregnancy.
* Systemic corticosteroid use or inflammatory rheumatic diseases.
* Cognitive impairment or psychiatric illness preventing comprehension of questionnaire instructions.
* Lack of a prior EMG report upon admission to the outpatient clinic.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Median Nerve Flattening Ratio (FR)
Timeframe: At baseline (T0), 3rd week (T1), and 12th week (T2)
2
Median Nerve Cross-Sectional Area (CSA)
Timeframe: At baseline (T0), 3rd week (T1), and 12th week (T2)